Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2

Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2

Pediatric, adolescent and young adult (AYA) patients receiving novel cancer immunotherapies may develop associated toxicities with overlapping signs and symptoms that are not always easily distinguished from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection/clinical sequelae. We...

Full description

Bibliographic Details
Main Authors: Dristhi Ragoonanan, Sajad J. Khazal, Rodrigo Mejia, Linette Ewing, Jean-Bernard Durand, Lara Bashoura, Jean Tayar, Natalie Dailey Garnes, Demetrios Petropoulos, Priti Tewari, Micah Bhatti, Ali Haider Ahmad, Jose Cortes, Shehla Razvi, Katrina McBeth, Rita Swinford, Basirat Shoberu, Waseem Waseemuddin, Linda Chi, Jonathan B. Gill, Wafik Zaky, Najat Daw, Cristina Gutierrez, Welela Tereffe, Partow Kebriaei, Katayoun Rezvani, Elizabeth J. Shpall, Richard E. Champlin, Kris M. Mahadeo
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-02-01
Series:Frontiers in Oncology
Subjects:
SARS-CoV-2
cancer immunotherapy
MIS-C
MIS-A
COVID-19
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2021.625707/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2021.625707/full

Similar Items